LONG-TERM NEUROSTIMULATOR PROGRAMMING IN A LARGE PROSPECTIVE TRIAL OF SACRAL NEUROMODULATION THERAPY FOR OVERACTIVE BLADDER PATIENTS

被引：0
作者：
Siegel, S. [1 ]
Mangel, J. [2 ]
Bennett, J. [3 ]
Comiter, C., V [4 ]
Zylstra, S. [5 ]
Bird, E. [6 ]
Griebling, T. L. [7 ]
Sutherland, S. E. [8 ]
Berg, Chase K. [9 ]
Kan, F. [9 ]
机构：
[1] Metro Urol, Woodbury, MN USA
[2] MetroHlth Med Ctr, Cleveland, OH USA
[3] Mercy Hlth Pelv Med & Urogynecol, St Louis, MO USA
[4] Stanford Univ, Stanford, CA 94305 USA
[5] Milford Reg Med Ctr, Milford, MA USA
[6] Scott & White Healthcare, Dallas, TX USA
[7] Univ Kansas, Lawrence, KS 66045 USA
[8] Univ Washington, Seattle, WA 98195 USA
[9] Medtronic, Minneapolis, MN USA
来源：
NEUROUROLOGY AND URODYNAMICS | 2018年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
435
引用
收藏
页码：S282 / S282
页数：1
相关论文
共 50 条
  • [21] Pudendal nerve stimulation therapy of the overactive bladder -: An alternative to sacral neuromodulation?
    Seif, C
    van der Horst, C
    Naumann, CM
    Jünemann, KP
    Bosch, R
    Buller, J
    Braun, PM
    [J]. AKTUELLE UROLOGIE, 2005, 36 (03) : 234 - 238
  • [22] Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients
    Reekmans, Mathias
    Janssen, Janine M. W.
    Vrijens, Desiree M. J.
    Smits, Martijn A. C.
    van Koeveringe, Gommert A.
    Van Kerrebroeck, Philip E. V. A.
    [J]. NEUROUROLOGY AND URODYNAMICS, 2021, 40 (05) : 1120 - 1125
  • [23] Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
    Amin, Katherine
    Moskowitz, Dena
    Kobashi, Kathleen C.
    Lee, Una J.
    Lucioni, Alvaro
    [J]. JOURNAL OF UROLOGY, 2019, 201 (05) : 973 - 978
  • [24] DO PATIENTS DISCONTINUE OVERACTIVE BLADDER MEDICATIONS AFTER SACRAL NEUROMODULATION?
    Amin, Katherine
    Moskowitz, Dena
    Kobashi, Kathleen C.
    Lee, Una J.
    Lucioni, Alvaro
    [J]. JOURNAL OF UROLOGY, 2018, 199 (04) : E1015 - E1015
  • [25] DO PATIENTS DISCONTINUE OVERACTIVE BLADDER MEDICATIONS AFTER SACRAL NEUROMODULATION?
    Amin, Katherine
    Moskowitz, Dena
    Kobashi, Kathleen
    Lee, Una
    Lucioni, Alvaro
    [J]. NEUROUROLOGY AND URODYNAMICS, 2018, 37 : S569 - S569
  • [26] Long-term adherence to clinical therapy of overactive bladder
    Drake, Marcus John
    [J]. TRANSLATIONAL ANDROLOGY AND UROLOGY, 2017, 6 (03) : 602 - 603
  • [27] Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
    Trinh, Hamilton
    Irish, Vicki
    Diaz, Mireya
    Atiemo, Humphrey
    [J]. INTERNATIONAL NEUROUROLOGY JOURNAL, 2019, 23 (03) : 226 - 233
  • [28] Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial
    Kinjo, Manami
    Sekiguchi, Yuki
    Yoshimura, Yasukuni
    Nutahara, Kikuo
    [J]. LUTS-LOWER URINARY TRACT SYMPTOMS, 2018, 10 (02) : 148 - 152
  • [29] Combination of Sacral Neuromodulation and Tolterodine for Treatment of Idiopathic Overactive Bladder in Women: A Clinical Trial
    Tang, Hua
    Chen, Jian
    Wang, Yongfu
    Yu, Ting
    Guo, Changping
    Liao, Xiaoqi
    [J]. UROLOGY JOURNAL, 2014, 11 (04) : 1800 - 1805
  • [30] LONG-TERM (>8Y.) FUNCTIONAL OUTCOMES OF S3 SACRAL NEUROMODULATION FOR THE TREATMENT OF IDIOPATHIC OVERACTIVE BLADDER
    Chartier-Kastler, Emmanuel
    Ismail, Salima
    Perrouin-Verbe, Marie-Aimee
    Modestine, Johan Rose Dit
    Denys, Pierre
    Phe, Veronique
    [J]. NEUROUROLOGY AND URODYNAMICS, 2018, 37 : S649 - S650
12345